

Evonik opens new office in Pakistan

December 6, 2018

- The new Pakistan office will strengthen Evonik’s local presence, leveraging on market opportunities
- Evonik to continue building closer relationships with Pakistani customers

Contact Person
Simone Fibiger
Head of Regional Communication
Asia Pacific South
Phone +65 6809 6820
simone.fibiger@evonik.com

Karachi, Pakistan – Evonik, one of the world leaders in specialty chemicals, inaugurated its new office in Pakistan on December 4, 2018. The legal entity was established to support the company’s strategic and long-term growth plans in the country.

Located in the megacity of Karachi, the new office represents another important milestone for Evonik since its first representative office was opened in the country in 2004. Tapping into Pakistan’s emerging and dynamic business landscape, the company will focus on strengthening its local presence as well as expanding capabilities for its various business lines including Animal Nutrition, Silica, Oil Additives, Health Care, Personal Care and Interface & Performance.

“With our dedicated local sales and business development team, we are now even better positioned to serving our customers. At the same time, we remain committed to contributing to Pakistan’s economic development through our innovative, sustainable solutions,” said Peter Meinshausen, Regional President of Evonik Asia Pacific South during the opening ceremony. “Over the past decade, we have built strong relationships with our customer base here. We see a lot of potential in several areas and setting up a full-fledged entity in Pakistan is a logical step in our growth strategy.”

Evonik Pakistan is a wholly-owned subsidiary of Evonik Industries. Active in over 100 countries around the world, Evonik has a strong product portfolio for multiple industry applications including but not limited to Health Care, Animal Nutrition, Resource Efficiency, and Performance Materials.

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Dr. Werner Müller, Honorary Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

Evonik Asia Pacific South

Headquartered in Singapore, Evonik is present in the Asia Pacific South region with production sites, sales offices, innovation and technical service centers located in Australia, Bangladesh, India, Indonesia, Malaysia, New Zealand, Pakistan, Philippines, Singapore, Thailand and Vietnam. With more than 1,800 employees in the region, the company steadily grows its footprint in Asia Pacific South by expanding its regional operations in response to the growing demand. Evonik Industries has been establishing customer relationships and importing a broad range of products in the Asia Pacific South region since the 1920's.

Disclaimer

Insofar as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.